Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
27th Mar 20185:44 pmRNSPublication of Suppl.Prospcts
9th Mar 20184:16 pmRNSAnnual Financial Report
8th Mar 20183:30 pmRNSDividend Declaration
2nd Mar 201812:34 pmRNSStatement re Offer for Subscription
13th Feb 20183:34 pmRNSTransaction in Own Shares
6th Feb 20185:14 pmRNSDirector/PDMR Shareholding
6th Feb 20185:13 pmRNSDirector/PDMR Shareholding
6th Feb 20185:12 pmRNSDirector/PDMR Shareholding
6th Feb 20185:06 pmRNSIssue of Equity
24th Jan 20184:41 pmRNSPublication of Suppl.Prospcts
19th Jan 20183:33 pmRNSNet Asset Value(s)
30th Nov 20174:31 pmRNSIssue of Equity
22nd Nov 20175:06 pmRNSTransaction in Own Shares
21st Nov 20173:45 pmRNSIssue of Equity
17th Nov 20175:05 pmRNSStatement re NAV and Dividend Investment Scheme
8th Nov 201710:11 amRNSResult of General Meeting
27th Oct 20173:26 pmRNSNet Asset Value(s)
25th Oct 20172:57 pmRNSDividend Declaration
22nd Sep 20176:25 pmRNSStatement re Offer for Subscription
22nd Sep 20176:25 pmRNSStatement re Offer for Subscription
15th Sep 20174:45 pmRNSIssue of Equity
15th Sep 201710:05 amRNSStatement re NAV and Dividend Investment Scheme
6th Sep 201711:37 amRNSForm 8.3 - Byotrol Plc
31st Aug 20175:01 pmRNSTransaction in Own Shares
25th Aug 20172:29 pmRNSHalf-year Report
10th Aug 20174:31 pmRNSDividend Declaration
25th Jul 201712:55 pmRNSForm 8.3 - Work Group PLC
19th Jul 201712:20 pmRNSStatement re Intended Offers for Subscription
19th Jul 201712:20 pmRNSStatement re Intended Offers for Subscription
10th Jul 201710:56 amRNSNet Asset Value(s)
15th Jun 20174:00 pmRNSDividend Declaration
12th May 20174:13 pmRNSTransaction in Own Shares
12th May 20174:07 pmRNSNet Asset Value(s)
11th May 20172:39 pmRNSTransaction in Own Shares
10th May 201712:33 pmRNSTransaction in Own Shares
28th Apr 20173:36 pmRNSDirectorate Change
27th Apr 20171:01 pmRNSNet Asset Value(s)
27th Apr 201712:57 pmRNSResult of AGM
24th Mar 20175:33 pmRNSAnnual Financial Report
26th Jan 20177:00 amRNSNet Asset Value and Proposed Final Dividend
20th Jan 201710:12 amRNSDirectorate Change
8th Nov 20164:49 pmRNSTransaction in Own Shares
7th Nov 201611:00 amRNSDirector/PDMR Shareholding
28th Oct 20168:39 amRNSNet Asset Value(s)
26th Aug 20164:36 pmRNSTransaction in Own Shares
21st Jul 20164:53 pmRNSHalf-year Report
13th Apr 20161:14 pmRNSDirectorate Change
13th Apr 20161:08 pmRNSResult of AGM
13th Apr 201612:52 pmRNSNet Asset Value(s)
11th Mar 20167:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.